Beneficial Effects of Sacubitril/valsartan in Heart Failure with Reduced Ejection Fraction: Pas à Cause Du BNP?

Overview

Journal Eur J Heart Fail

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2019 Mar 6

PMID 30834697

Citations 1

Authors

Naveen L Pereira

Viral K Desai

Allan S Jaffe

Affiliations

Soon will be listed here.

Citing Articles

B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?.

Nishikimi T, Nakagawa Y Biology (Basel). 2022; 11(7).

PMID: 36101415 PMC: 9312360. DOI: 10.3390/biology11071034.

References

Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D . Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovasc Ther. 2016; 34(4):191-8. PMC: 5108443. DOI: 10.1111/1755-5922.12183. View

DeVore A, Braunwald E, Morrow D, Duffy C, Ambrosy A, Chakraborty H . Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2019; 5(2):202-207. PMC: 6990764. DOI: 10.1001/jamacardio.2019.4665. View

Bayes-Genis A, Barallat J, Richards A . A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. J Am Coll Cardiol. 2016; 68(6):639-653. DOI: 10.1016/j.jacc.2016.04.060. View

Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T . Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002; 71(23):2701-12. DOI: 10.1016/s0024-3205(02)01990-2. View

Seferian K, Tamm N, Semenov A, Tolstaya A, Koshkina E, Krasnoselsky M . Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem. 2008; 54(5):866-73. DOI: 10.1373/clinchem.2007.100040. View

Ruilope L, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz M . Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375(9722):1255-66. DOI: 10.1016/S0140-6736(09)61966-8. View

Kawamura M, Imanashi M, Matsushima Y, Ito K, Hiramori K . Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol. 1992; 19(8):547-53. DOI: 10.1111/j.1440-1681.1992.tb00503.x. View

Vodovar N, Seronde M, Laribi S, Gayat E, Lassus J, Boukef R . Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014; 35(48):3434-41. DOI: 10.1093/eurheartj/ehu314. View

Vodovar N, Seronde M, Laribi S, Gayat E, Lassus J, Januzzi Jr J . Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. JACC Heart Fail. 2015; 3(8):629-36. DOI: 10.1016/j.jchf.2015.03.011. View

10.

Nougue H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F . Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2018; 21(5):598-605. DOI: 10.1002/ejhf.1342. View

11.

Packer M, McMurray J, Desai A, Gong J, Lefkowitz M, Rizkala A . Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2014; 131(1):54-61. DOI: 10.1161/CIRCULATIONAHA.114.013748. View

12.

Januzzi J, Butler J, Fombu E, Maisel A, McCague K, Pina I . Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Am Heart J. 2018; 199:130-136. DOI: 10.1016/j.ahj.2017.12.021. View

13.

Helske S, Laine M, Kupari M, Lommi J, Turto H, Nurmi L . Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J. 2007; 28(15):1894-903. DOI: 10.1093/eurheartj/ehm129. View

14.

McMurray J, Packer M, Desai A, Gong J, Lefkowitz M, Rizkala A . Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11):993-1004. DOI: 10.1056/NEJMoa1409077. View

15.

Pereira N, Aksoy P, Moon I, Peng Y, Redfield M, Burnett Jr J . Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010; 49(5):864-74. PMC: 3092155. DOI: 10.1016/j.yjmcc.2010.07.020. View

16.

Vasile V, Jaffe A . Natriuretic Peptides and Analytical Barriers. Clin Chem. 2017; 63(1):50-58. DOI: 10.1373/clinchem.2016.254714. View

17.

Zile M, Claggett B, Prescott M, McMurray J, Packer M, Rouleau J . Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016; 68(22):2425-2436. DOI: 10.1016/j.jacc.2016.09.931. View

18.

Charles C, Espiner E, Nicholls M, Richards A, Yandle T, Protter A . Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996; 271(2 Pt 2):R373-80. DOI: 10.1152/ajpregu.1996.271.2.R373. View

19.

Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H . Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res. 2003; 26 Suppl:S121-7. DOI: 10.1291/hypres.26.s121. View

20.

Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg H, Bartunek J . Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 2002; 105(3):286-9. DOI: 10.1161/hc0302.103593. View